ArticleEuropean journal of radiology open2025
MRI-derived extracellular volume fraction as a prognostic biomarker for early recurrence after R0 resection of pancreatic ductal adenocarcinoma.
Article in European journal of radiology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T1 Mapping-Derived Extracellular Volume Fraction for Non-Invasive Assessment of Tumor-Stroma Ratio in Rectal Cancer.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence risk after R0 resection. This study aimed to evaluate the prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic parameters, including volume transfer constant (K Methods: In this retrospective cohort study, 61 patients (mean age 60.7 ± 9.7 years; 35 males) with histologically confirmed PDAC underwent preoperative 3 T MRI between January 2017 and May 2024, including DCE-MRI and dual-time-point T1 mapping. Two radiologists independently measured K Results: ECV demonstrated excellent reproducibility (ICC = 0.99) and independently predicted shorter RFS (HR = 1.020; 95 % CI: 1.003-1.038; p = 0.022). An optimal ECV cutoff of 31.99 % effectively stratified patients into high- and low-risk groups with significantly different median RFS (10.9 vs. 17.4 months, p = 0.012). However, other DCE-MRI parameters (K Conclusion: MRI-derived tumor ECV is a robust, reproducible biomarker for predicting early recurrence after R0 resection in PDAC patients, potentially assisting in preoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.